Cardea Bio Adds $6.5 Million to Series A; Early-Stage Financing Now Totals More Than $20 Million
01/12/21, 3:09 PM
Location
san diegoMoney raised
$6 million
Round Type
series a
Cardea Bio, Inc., a Tech+Bio company integrating molecular biology with semiconductors via Graphene-based biology-gated Transistors, announced today a $6.5M series A extension that brings the A round total above $20M. The new capital infusion is led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors. Proceeds from the financing will be used to further develop Cardea’s proprietary Transistor platform, in order to significantly expand mass-manufacturing and further grow Cardea’s number of commercial partnerships.
Company Info
Company
Cardea Bio Inc.
Location
san diego, california, united states
Additional Info
Cardea is linking computers to the LIVE molecular signals running biology. Its multi-omics technology consists of a Tech+Bio Infrastructure (hardware, software and wetware) and Chipsets manufactured with proprietary Graphene-based Biology-gated Transistors, or Cardean Transistors™ for short.